Moderna, Inc. (NASDAQ:MRNA) Holdings Decreased by Bessemer Group Inc.

Bessemer Group Inc. trimmed its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 11.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,962 shares of the company’s stock after selling 658 shares during the period. Bessemer Group Inc.’s holdings in Moderna were worth $206,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of MRNA. Wilmington Savings Fund Society FSB lifted its position in shares of Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares in the last quarter. Venturi Wealth Management LLC increased its stake in Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after buying an additional 664 shares during the period. Compass Planning Associates Inc purchased a new stake in Moderna in the 4th quarter worth approximately $37,000. Crowley Wealth Management Inc. acquired a new stake in shares of Moderna during the 4th quarter valued at $41,000. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in shares of Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after acquiring an additional 389 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Price Performance

Shares of Moderna stock opened at $25.19 on Thursday. The company has a market cap of $9.74 billion, a PE ratio of -2.71 and a beta of 2.23. The firm has a fifty day moving average price of $31.10 and a two-hundred day moving average price of $40.37. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $170.47.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several recent research reports. Citigroup began coverage on Moderna in a report on Thursday, March 13th. They set a “neutral” rating and a $40.00 price objective for the company. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $40.00 price target on shares of Moderna in a research note on Tuesday, February 18th. Berenberg Bank boosted their price target on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Barclays lowered shares of Moderna from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. Finally, UBS Group decreased their target price on shares of Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, February 19th. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $58.70.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.